MYCN and medulloblastoma: A research paper in this topic shows that newly engineered PI3K inhibitors, PIK-75 and PW-12, are able to destroy the MYCN protein in mouse models of neuroblastoma and medulloblastoma, suggesting that they might be developed into useful drugs for these cancers (8).